We have shown previously that increased concentrations of plasma soluble fibrin monomer complexes (SFMC) and elevated fibronectin (Fn) levels are closely related to the development of diabetic microangiopathy. The purpose of the present study was to explore whether or not changes in plasma glucose levels could have an effect on these protein constituents. Plasma glucose levels of 25 uncontrolled diabetic patients were brought under control with insulin and serial measurements of SFMC and Fn were made over a period of 4 weeks. Glucose values fell from an average of 312 mg 100 ml to 160 mg 100 ml. Ten patients with macroproteinuria (i.e.>_ 0.5 g/24 hr) showed initially elevated plasma SFMC and Fn concentrations. These levels fell significantly over the 4 week observation period : from 13.6 mg/ 100 ml to 9.4 mg 100 ml for SFMC and from 38.4 mg 100 ml to 34.5 mg 100 ml for Fn. The remaining 15 patients had nearly normal levels of both SFMC (7.9 mg/ 100 ml) and Fn (31.1 mg 100 ml) and glycemic control brought no further reduction. The data indicated that a) elevated SFMC and Fn levels are indeed associated with diabetic microangiopathy, especially in the presence of macroproteinuria ; and b) adequate glycemic control is capable of normalizing the plasma concentration of these constituents.
It is well known that plasma soluble fibrin monomer complexes (SFMC) consist of the fibrin monomer, fibrinogen and fibrin degradation products. Fibrin monomer production essentially requires thrombin for the partial proteolysis of fibrinogen. In addition, the levels of SFMC closely correlates to that of /3-thromboglobulin (Iioka 1984) . Hence, the increase in the levels of SFMC is an indicator of the intracapillary thrombin activation.
Our recent studies revealed that plasma levels of SFMC and Fn in diabetics with advanced diabetic microangiopathy, especially in the presence of macroproteinuria, were higher than those seen in patients without diabetic microangiopathy.
Moreover, plasma Fn level 1986) . Thus, we propose that high levels of SFMC and Fn as markers of enhanced generation of intracapillary thrombin may be useful in monitoring the development and progression of diabetic microangiopathy. The purpose of the present study was to explore whether adequate glycemic control with insulin could have an effect on these protein constituents.
SUBJECTS AND METHODS
The clinical details of subjects are given in Table 1 . Twenty-five uncontrolled diabetics were studied. The patients were divided into two groups, according to degree of TABLE 1. Clinical characteristics of subjects proteinuria, namely, microproteinuria (rates of total urinary protein excretion ; up to 0.5 g/ 24 hr) and macroproteinuria, (above 0.5 g/24 hr). Group A had macroproteinuria, and comprised 10 diabetics, 3 males and 7 females. The ages ranged from 31 to 70 years (mean 60 years) and the history of diabetes was, on the average, 11 years. There were 4 patients with simple diabetic retinopathy, 3 with pre-proliferative diabetic retinopathy and 3 with proliferative diabetic retinopathy. Urinary protein excretion ranged from 0.5 to 20 g/24 hr (mean 5.0 g/24 hr). Group B comprised 15 diabetics with microproteinuria ; 7 males and 8 females patients with ages ranging from 29 to 70 years (mean 48 years). The duration of diabetes was much shorter in this group, the average being 5 years. There were 10 patients without signs of diabetic retinopathy, 3 with simple diabetic retinopathy, 1 with preproliferative diabetic retinopathy. All patients in both groups were treated with insulin to bring their diabetes under adequate control.
Venous blood was drawn from each patients, after an overnight fast, at intervals of 2 weeks. A total of 3 blood samples was taken from each patient over the 4 week observation period for measurements of plasma glucose, SFMC and Fn. The mean plasma glucose (MPG) value was a mean calculated from plasma glucose levels measured before the main meal, 2 hr postprandially and at night time.
SFMC was determined according to the method of Shoda and Masukata (1980) with the following modifications. Five ml of 10 mM veronal buffer, pH 8.0, containing 0.1% protamine sulfate and 0.3 M NaCI was heated to 37°C and added to 0.1 ml citrated plasma. After incubation at 37°C for 30 min, the solution was filtered through "Separax" cellulose acetate paper (Jookoo Co., Ltd., Tokyo). The filter paper was subsequently washed with the same buffer, then with 0.1 M phosphate buffer, pH 7.2, then stained with 0.8% Ponceau 3R in 10% trichloroacetic acid. After destaining with 2% acetic acid, the protein-bound pigment was extracted with 2 ml of 0.01 N NaOH. The protamine-precipitable protein was quantitated spectrophotometrically at O.D. 500 nm using a purified fibrin monomer as a standard.
Plasma Fn was assayed in citrated plasma by an immunoturbidimetric assay, using calibrated Fn standards and monospecific antibody to Fn supplied in kits purchased from Beohringer Mannheim, GmbH. Biochemica (Mannheim, FRG).
Glucose concentrations in plasma were determined by the glucose oxidase procedure, using a Beckman Analyser (Beckman Instruments, Inc., Fullerton, CA, USA).
The amount of protein in 24 hr urine collections was quantitatively determined by the method of Kingsbury-Clark (Kingsbury et al. 1926 ).
Data were expressed as means +s.E. Statistical analyses were performed by the Student's t-test.
RESULTS
Mean plasma glucose, SFMC and Fn levels for all 25 patients are presented in Fig. 1 . Zero time values were determined in blood samples taken prior to incentive insulin treatment and the other two values came from samples taken when the diabetic state was ameliorated. It should be noted that SFMC levels dropped from 10.2 to 7.6 mg/100 ml and no change was observed in Fn values. However, when the diabetics were divided into two separate groups on the basis of macro-and microproteinuria, the data, especially for Fn, are different.
The results from Group A and B are presented in Table 2 . Patients in Group A had SFMC levels before insulin treatment that were remarkably higher than both age-matched healthy controls (5.7+0.4 mg/100 ml) and Group B. The SFMC levels at 2 and 4 weeks after treatment were significantly reduced and were approaching normal values. The Fn levels before treatment were also higher compared with those of age-matched healthy controls (32.2±0.5 mg/ 100 ml) and Group B. The values were significantly decreased by 4 weeks of glycemic control.
In Group B, only the MPG levels were similar to those of Group A. The SFMC and Fn levels before insulin treatment were significantly lower in Group B than in Group A and reductions over the 4 week period were negligible. Jones (1985) reported that hyperglycemia induced by an oral glucose challenge was accompanied by a rise in plasma fibrinopeptide-A concentration, which indicates augmented thrombin activity. The author claims that the changes in hemodynamics associated with hyperglycemia may also trigger intra-and/or extravascular fibrin formation depending on the degree of vascular disease. Furthermore, non-enzymatic glycosylation was shown to reduce antithrombin III activity (Ceriello et al. 1983) , and a decrease in antithrombin III activity was shown to go parallel with hyperglycemia (Ceriello et al. 1987) .
Plasma Fn is a glycoprotein similar to that which exists on the surface of fibroblasts and endothelial cells, and these cells produce Fn. In addition, platelets release a small amount of Fn when stimulated with thrombin or collagen (Plow et al. 1979 ). An increase of plasma Fn levels in poorly controlled diabetic patients was reported in the literature previously, and elevated plasma Fn levels could be due to enhanced vessel wall production or due to increased release from platelets (Schwarz and Schernthaner 1982) . It was also found that elevated Fn levels are not influenced by a short-term (4 day) intravascular insulin infusion (Davis 1981) . Thus, the effect of long-term glycemic control on high Fn levels, as 
